Intrexon (XON) Downgraded to “Strong Sell” at ValuEngine

ValuEngine cut shares of Intrexon (NYSE:XON) from a sell rating to a strong sell rating in a report issued on Sunday, December 31st.

Several other brokerages have also weighed in on XON. Zacks Investment Research lowered shares of Intrexon from a hold rating to a sell rating in a research report on Monday, October 16th. Northland Securities reaffirmed a buy rating and set a $27.00 price objective on shares of Intrexon in a research report on Friday, October 6th. Griffin Securities reaffirmed a buy rating and set a $55.00 price objective on shares of Intrexon in a research report on Friday, October 6th. JMP Securities reaffirmed an outperform rating and set a $42.00 price objective on shares of Intrexon in a research report on Thursday, October 5th. Finally, Stifel Nicolaus raised their price objective on shares of Intrexon from $39.00 to $57.00 and gave the company a buy rating in a research report on Friday, November 10th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Intrexon presently has a consensus rating of Hold and a consensus target price of $38.50.

Shares of Intrexon (XON) opened at $13.77 on Friday. The company has a current ratio of 2.05, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01. The company has a market cap of $1,660.00, a P/E ratio of -12.29 and a beta of 1.33. Intrexon has a fifty-two week low of $10.26 and a fifty-two week high of $26.99.

Intrexon (NYSE:XON) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.02. Intrexon had a negative net margin of 66.88% and a negative return on equity of 18.68%. analysts anticipate that Intrexon will post -1.06 EPS for the current year.

Several large investors have recently added to or reduced their stakes in XON. Steward Partners Investment Advisory LLC bought a new position in shares of Intrexon in the third quarter valued at approximately $121,000. Tower Research Capital LLC TRC raised its position in shares of Intrexon by 2,031.7% in the second quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 4,937 shares during the period. SG Americas Securities LLC bought a new position in shares of Intrexon in the third quarter valued at approximately $139,000. Federated Investors Inc. PA bought a new position in shares of Intrexon in the second quarter valued at approximately $172,000. Finally, Quantbot Technologies LP raised its position in shares of Intrexon by 423.7% in the third quarter. Quantbot Technologies LP now owns 9,993 shares of the biotechnology company’s stock valued at $189,000 after purchasing an additional 8,085 shares during the period. 77.45% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Intrexon (XON) Downgraded to “Strong Sell” at ValuEngine” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/17/valuengine-downgrades-intrexon-xon-to-strong-sell.html.

About Intrexon

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply